Apricus Biosciences, Inc.
Apricus Biosciences to Announce Corporate Update and First Quarter 2016 Financial Results
SAN DIEGO, 2016-05-03 13:00 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's first quarter 2016 financial results will be released on Monday, May 9, 2016 at 7:00 a.m. Eastern Time.
Apricus will host a thought leader event on May 9 at 11:00 a.m. ET in lieu of the update conference call. The live webcast with presentation slides and subsequent replay of the event will be available atwww.apricusbio.com. If you would like to ask a question during the live Q&A, please submit your request via email email@example.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. To participate by telephone, please dial (877) 841-3961 (Domestic) or (201) 689-8589 (International). The conference ID number is 13633850. The archived webcast will remain available for 30 days following the live presentation.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus’ commercial product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus’ marketing partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals), Mylan NV and Elis Pharmaceuticals Ltd. Apricus currently has one active product candidate, RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon.
For further information on Apricus, visithttp://www.apricusbio.com.
*Vitaros®is a registered trademark of NexMed International Limited. Such trademark is registered in certain countries throughout the world and pending registration in the United States.
CONTACT: Institutional / Retail Investors: Matthew Beck
The Trout Group LLC
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Nasdaq22.1.2018 12:31 | pressemeddelelse
Agency for the Cooperation of Energy Regulators (ACER) continues to use Nasdaq's SMARTS for Pan-European Market Monitoring of EU Wholesale Energy Markets
Amdocs22.1.2018 12:01 | pressemeddelelse
Bell Canada Reaches Milestone in Network 3.0 Vision with Open Network Automation Platform (ONAP) and Strategic Partnership with Amdocs
World Finance22.1.2018 11:53 | pressemeddelelse
Alvogen CEO Robert Wessman speaks exclusively to World Finance about new opportunities in generic pharmaceuticals
Aryaka22.1.2018 06:02 | pressemeddelelse
SD-WAN Market Leader Aryaka Names Claudio Perugini Senior Vice President of Global Channels
Ant Financial Services Group20.1.2018 06:41 | pressemeddelelse
Ant Financial Hosts Technology Conference in Silicon Valley
Global Infrastructure Partners19.1.2018 17:29 | pressemeddelelse
Equis and Global Infrastructure Partners Announce Closing of US$5.0 Billion Renewable Energy Generation Acquisition of Equis Energy
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum